According to Future Market Insights, the global digital pathology market is anticipated to reach US$6,199 million by 2022. By 2032, the market for products and services related to digital pathology is anticipated to be worth US$ 22,870.2 Million, expanding at a 13.5% CAGR.
Due to technological developments and the widespread use of electronic medical records in the healthcare industry, digital pathology solutions are growing in popularity. Through 2032, cloud-based information systems are anticipated to grow at a 16.9% CAGR, while on-premise systems will maintain their leadership with a market value of US$ 626.8 million.
The increased use of advanced analytics in pharma and medical testing are two key factors boosting the digital pathology market’s adoption. Healthcare financing organizations and government bodies are implementing analytics through claim management and fraud prevention, which is fueling the market growth.
Get access to your Sample Report for more information:
https://www.futuremarketinsights.com/reports/sample/rep-gb-124
Surge in R&D in Digital Pathology to Augment Sales in Forthcoming Years
In recent years, the digital pathology industry has increased investments in biosimilar research and development initiatives, primarily for cancer treatment and Covid-19 treatment, which have substantially fuelled the market expansion.
Contract Research Organizations (CROs), in-vitro diagnostics (IVD) laboratories, clinical laboratories, and regulatory consultants are being assigned biosimilar development responsibilities by pharmaceutical corporations. These enterprises are developing in order to provide more cost-efficient solutions to their customers, requiring the use of digital pathology instruments to diagnose, research, and design effective healthcare solutions.
Cancer diagnostic Opens New Avenues for Digital Pathology Companies
Due to the sheer increasing occurrence of cancer, there is an increase in spending on digital pathology equipment. Complications arising from late cancer diagnosis, particularly in the case of blood cancer and lung cancer, necessitate the use of significant capital resources during therapy and diagnosis. The success of digital pathology in research is driving demand for these systems in the cancer research industry. This is also encouraging government investors to invest in digital pathology systems for clinical diagnosis. A significant amount of money is spent on cancer diagnosis and therapy monitoring. This explains why digital pathology solutions are in high demand.
Competitive Landscape
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Huron Technologies International Inc.
- Koninklijke Philips N.V.
- Olympus Corporation
- Hamamatsu Photonics K.K.
- Carl Zeiss AG
- Nikon Corporation
- 3DHISTECH Ltd.
- Hologic Inc.
- PerkinElmer, Inc.
- Visiopharm
- OptraSCAN, Inc.
- Inspirata, Inc.
- Sectra AB
Unlock your investment potential today! Gain exclusive insights and expert analysis with our comprehensive analyst report:
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-124
Some of the recent developments in digital pathology market are as follows:
- In May 2021, Leica Biosystems joined the European Society for Digital and Integrative Pathology (ESDIP) to assist pathology labs in developing laboratories in accordance with modern digital pathology instruments.
- In March 2021, Roche inked a comprehensive merger agreement with GenMark Diagnostics to broaden its product and distribution channel for European consumers.
Key Segments Profiled in the Global Digital Pathology Market
Digital Pathology by Product Type:
- Digital Pathology Equipment
- Whole Slide Scanners
- Brightfield Slide Scanners
- Fluorescence Slide Scanners
- Combination Slide Scanners
- Clinical Microscope
- Tissue Microarrays
- Digital Pathology Software
- Image Viewing and Analysis Software
- On-premise
- Cloud-based
- Digital Pathology Information Systems
- On-premise
- Cloud-based
- Digital Pathology Services
- Installation and Integration Services
- Consulting Services
- Maintenance and Validation Services
Digital Pathology by Application:
- Clinical Pathology
- Molecular Diagnostics
- Basic & Applied Research
- Drug Development
- Others
Digital Pathology by End User:
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Forensic Laboratories
- Research Institutes
- Contract Research Organizations (CROs)
- Clinics
Tailored Perspectives Await: Craft Your Personalized Report Experience Now :https://www.futuremarketinsights.com/customization-available/rep-gb-124
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
